Immunovia: Patrik Dahlen and Mats Grahn

Immunovia appointed Patrik Dahlen as its new CEO starting Nov. 1. Dahlen succeeds Mats Grahn, who has been nominated as a member of Immunovia's board.

Dahlen has served as CEO of several diagnostic companies. As CEO of Dako, he implemented a strategic repositioning of the company as a supplier of cancer diagnostics, which resulted in its acquisition by Agilent Technologies for $2.2 billion. As president of life sciences at Perkin Elmer, he was instrumental in building the company's diagnostics business with a niche focus on diagnostic systems for neonatal and prenatal screening.